<DOC>
	<DOCNO>NCT01847274</DOCNO>
	<brief_summary>This Phase 3 , multicenter , randomize , double-blind , placebo-controlled study niraparib maintenance platinum sensitive ovarian cancer patient either gBRCAmut tumor high-grade serous histology respond recent chemotherapy contain platinum agent . Niraparib orally active PARP inhibitor . Niraparib placebo ( 2:1 ratio ) administer daily continuously 28-day cycle . Health-related quality life measure Functional Assessment Cancer Therapy - Ovarian Symptom Index ( FOSI ) , European Quality Life scale , 5-Dimensions ( EQ-5D ) , neuropathy questionnaire . Safety tolerability assess clinical review adverse event ( AEs ) , physical examination , electrocardiogram ( ECGs ) , safety laboratory value . The primary objective study evaluate efficacy niraparib maintenance therapy patient platinum sensitive ovarian cancer assess prolongation progression free survival ( PFS ) .</brief_summary>
	<brief_title>A Maintenance Study With Niraparib Versus Placebo Patients With Platinum Sensitive Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<criteria>18 year age old , female , race Histologically diagnose ovarian cancer , fallopian tube cancer primary peritoneal cancer High grade ( grade 3 ) serous histology know gBRCAmut Has receive least 2 previous course platinumcontaining therapy , disease consider platinum sensitive follow penultimate ( next last ) platinum course ( 6 month period penultimate platinum regimen progression disease ) Has respond last platinum regimen , remain response enrol study within 8 week completion last platinum regimen ECOG 01 Adequate bone marrow , kidney liver function Known hypersensitivity component niraparib Invasive cancer ovarian cancer within 2 year ( except basal squamous cell carcinoma skin definitely treat ) Symptomatic uncontrolled brain metastasis Is pregnant breast feeding Immunocompromised patient Known active hepatic disease Prior treatment know PARP inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>platinum sensitive</keyword>
	<keyword>gBRCAmut</keyword>
	<keyword>BRCA</keyword>
	<keyword>high-grade serous histology</keyword>
	<keyword>PARP inhibitor</keyword>
</DOC>